In a significant advancement for blood cancer treatment, researchers at the University of North Carolina have developed a novel immunotherapy that targets acute myeloid leukemia (AML) without harming healthy blood cells. The study, published in the journal Blood, was led by immunologist Gianpietro Dotti and hematologist Paul Armistead, who engineered immune cells to selectively destroy cancerous cells while leaving normal tissue intact.
Standard treatments for AML, such as chemotherapy and traditional immunotherapies, often struggle to differentiate between malignant and healthy cells, leading to severe side effects and limited efficacy. The new approach addresses this challenge by modifying immune cells to recognize a specific marker on AML cells, enabling a targeted attack that spares healthy blood tissue. This breakthrough could offer new hope for patients with AML, a disease with a five-year survival rate of only about 30%.
Further research could pave the way for more advanced, side-effect-free cancer therapies. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also focused on developing innovative cancer treatments, highlighting the broader industry effort to improve patient outcomes. The UNC team's work represents a critical step forward in the quest for safer and more effective immunotherapies.
The engineered immune cells, known as chimeric antigen receptor (CAR) T cells, were designed to target a protein called CD33, which is highly expressed on AML cells but also present on some normal blood cells. To avoid toxicity, the researchers incorporated a safety switch that allows the cells to be deactivated if necessary. In preclinical models, the treatment effectively eliminated AML while preserving healthy blood stem cells, a key advantage over existing therapies.
Dr. Dotti emphasized the potential impact of this approach, stating, "Our findings suggest that it is possible to harness the power of the immune system to fight AML without causing the severe side effects seen with current treatments." Dr. Armistead added, "This could change the standard of care for patients who have limited options."
The research is still in early stages, and clinical trials will be needed to determine safety and efficacy in humans. However, the results offer a promising foundation for developing next-generation immunotherapies that could transform the treatment landscape for AML and potentially other cancers.
